Brief: Alphamab Oncology Says Unit And Pfizer Enter Clinical Trial Agreement
27/03/2020 09:25
March 27 (Reuters) - Alphamab Oncology 9966.HK :
* UNIT AND PFIZER ENTER CLINICAL TRIAL AGREEMENT
* COLLABORATION WITH PFIZER ON KN026 IN COMBINATION WITH
IBRANCE(PALBOCICLIB) IN HER2+ BREAST CANCER
Source text for Eikon: ID:nHKS6p2C9d
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)